125 related articles for article (PubMed ID: 38018063)
1. [Efficacy and safety of pegylated interferon alpha-2b for patients with myeloproliferative neoplasm].
Teng GS; Zhang YH; Wang Y; Du CX; Li YQ; Hu NB; Xiang GP; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3645-3651. PubMed ID: 38018063
[No Abstract] [Full Text] [Related]
2. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.
Cao W; Li M; Zhang L; Lu Y; Wu S; Shen G; Chang M; Liu R; Gao Y; Hao H; Hu L; Yi W; Pan CQ; Xie Y
Biomed Res Int; 2021; 2021():2178143. PubMed ID: 33575322
[TBL] [Abstract][Full Text] [Related]
3. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
4. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342
[TBL] [Abstract][Full Text] [Related]
5. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
8. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
Pandit A; Bhalani N; Bhushan BLS; Koradia P; Gargiya S; Bhomia V; Kansagra K
Int J Infect Dis; 2021 Apr; 105():516-521. PubMed ID: 33713817
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
13. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
14. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C.
Hu JH; Chang ML; Huang TJ; Yeh CT; Chiu WN; Chiang MS; Chen MY
J Interferon Cytokine Res; 2019 Apr; 39(4):205-213. PubMed ID: 30855203
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
18. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C;
PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813
[TBL] [Abstract][Full Text] [Related]
19. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
20. Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.
Papasavvas E; Azzoni L; Pagliuzza A; Abdel-Mohsen M; Ross BN; Fair M; Howell BJ; Hazuda DJ; Chomont N; Li Q; Mounzer K; Kostman JR; Tebas P; Montaner LJ
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):433-443. PubMed ID: 33323024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
